Gilead Sciences (GILD) Stock Statistics & Valuation Metrics

Gilead Sciences has a market cap or net worth of CHF 173.49B. The enterprise value is CHF 204.66B.

Market Cap

CHF 173.49B

Enterprise Value

CHF 204.66B

Gilead Sciences has 1,239,955,200 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

1,239,955,200

Owned by Insiders

0.08%

Owned by Institutions

60.55%

Gilead Sciences’s return on equity (ROE) is 0.37 and return on invested capital (ROIC) is 20.32%.

Return on Equity (ROE)

0.37

Return on Assets (ROA)

0.14

Return on Invested Capital (ROIC)

20.32%

Return on Capital Employed (ROCE)

0.25

Revenue Per Employee

1.73M

Profits Per Employee

500.59K

Employee Count

17,000

Asset Turnover

0.50

Inventory Turnover

3.51

The current PE Ratio of Gilead Sciences is -54.95. Gilead Sciences’s PEG ratio is 0.42.

PE Ratio

-54.95

PS Ratio

6.82

PB Ratio

16.23

Price to FCF

15.05

Price to Operating Cash Flow

14.61

PEG Ratio

0.42

In the last 12 months, Gilead Sciences had revenue of 29.44B and earned 8.51B in profits. Earnings per share was 6.84.

Revenue

29.44B

Gross Profit

23.21B

Operating Income

11.70B

Pretax Income

9.80B

Net Income

8.51B

EBITDA

13.58B

Earnings Per Share (EPS)

6.84

In the last 12 months, operating cash flow was 14.48B and capital expenditures -442.00M, giving a free cash flow of 14.04B billion.

Operating Cash Flow

14.48B

Free Cash Flow

14.04B

Free Cash Flow per Share

11.30

Gilead Sciences pays an annual dividend of CHF 0.67, resulting in a dividend yield of 1.89%

Dividend Per Share

CHF 0.67

Dividend Yield

1.89%

Payout Ratio

37.63%

Free Cash Flow Yield

6.63%

Earnings Yield

-1.82%

Beta

0.30

52-Week Price Change

104.91%

50-Day Moving Average

123.41

200-Day Moving Average

108.61

Relative Strength Index (RSI)

84.31

Average Volume (3m)

25

Gilead Sciences upcoming earnings date is Feb 04, 2027, TBA (Not Confirmed).

Last Earnings Date

Oct 29, 2026

Next Earnings Date

Feb 04, 2027

Ex-Dividend Date

Jun 15, 2026

Gilead Sciences as a current ratio of 1.55, with Debt / Equity ratio of 109.84%

Current Ratio

1.55

Quick Ratio

1.40

Debt to Market Cap

0.16

Net Debt to EBITDA

1.28

Interest Coverage Ratio

11.43

In the past 12 months, Gilead Sciences has paid 1.29B in taxes.

Income Tax

1.29B

Effective Tax Rate

0.13

Gilead Sciences EV to EBITDA ratio is 281.28, with an EV/FCF ratio of 16.49.

EV to Sales

7.47

EV to EBITDA

281.28

EV to Free Cash Flow

16.49

EV to Operating Cash Flow

15.99

Gilead Sciences has CHF 6.44B in cash and marketable securities with CHF 26.23B in debt, giving a net cash position of -CHF 19.79B billion.

Cash & Marketable Securities

CHF 6.44B

Total Debt

CHF 26.23B

Net Cash

-CHF 19.79B

Net Cash Per Share

-CHF 15.96

Tangible Book Value Per Share

-CHF 7.07

Gross margin is 79.93%, with operating margin of -4.38%, and net profit margin of -12.47%.

Gross Margin

79.93%

Operating Margin

-4.38%

Pretax Margin

-8.17%

Net Profit Margin

-12.47%

EBITDA Margin

2.66%

EBIT Margin

-6.43%

The average price target for Gilead Sciences is CHF 142.34, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

CHF 142.34

Price Target Upside

2.34% Upside

Analyst Consensus

Strong Buy

Analyst Count

22

Revenue Growth Forecast

0.32%

EPS Growth Forecast

-143.99%

Smart Score

10

AI Score

―